These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 25940912)

  • 41. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.
    Tanaka Y; Tummala R
    Mod Rheumatol; 2021 Jan; 31(1):1-12. PubMed ID: 32814461
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG; Fusco BE
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Type I interferon and T helper 17 cells co-exist and co-regulate disease pathogenesis in lupus patients.
    Biswas PS; Aggarwal R; Levesque MC; Maers K; Ramani K
    Int J Rheum Dis; 2015 Jul; 18(6):646-53. PubMed ID: 25960196
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical development.
    Tocut M; Shoenfeld Y; Zandman-Goddard G
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1151-1162. PubMed ID: 32755494
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Type 1 interferons: A target for immune-mediated inflammatory diseases (IMIDs).
    Mathian A; Felten R; Alarcon-Riquelme ME; Psarras A; Mertz P; Chasset F; Vital EM; Arnaud L
    Joint Bone Spine; 2024 Mar; 91(2):105627. PubMed ID: 37640261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent advances in cytokines in cutaneous and systemic lupus erythematosus.
    Mikita N; Ikeda T; Ishiguro M; Furukawa F
    J Dermatol; 2011 Sep; 38(9):839-49. PubMed ID: 21767292
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IFN-γ, should not be ignored in SLE.
    Liu W; Zhang S; Wang J
    Front Immunol; 2022; 13():954706. PubMed ID: 36032079
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Systemic lupus and biotherapy: 2010 update].
    Arnaud L; Amoura Z
    Rev Med Interne; 2010 Dec; 31 Suppl 3():S296-303. PubMed ID: 21030117
    [No Abstract]   [Full Text] [Related]  

  • 49. Targeting interferon-alpha: a promising approach for systemic lupus erythematosus therapy.
    Schmidt KN; Ouyang W
    Lupus; 2004; 13(5):348-52. PubMed ID: 15230291
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-IFNαR Mabs for the treatment of systemic lupus erythematosus.
    Goulden B; Isenberg D
    Expert Opin Biol Ther; 2021 Apr; 21(4):519-528. PubMed ID: 33085537
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Toll-like receptors: potential targets for lupus treatment.
    Wu YW; Tang W; Zuo JP
    Acta Pharmacol Sin; 2015 Dec; 36(12):1395-407. PubMed ID: 26592511
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
    Tanaka Y; Takeuchi T; Okada M; Ishii T; Nakajima H; Kawai S; Nagashima T; Hayashi N; Wang L; Tummala R
    Mod Rheumatol; 2020 Jan; 30(1):101-108. PubMed ID: 30793642
    [No Abstract]   [Full Text] [Related]  

  • 53. Interleukin-17 in systemic lupus erythematosus: A comprehensive review.
    Li D; Guo B; Wu H; Tan L; Chang C; Lu Q
    Autoimmunity; 2015; 48(6):353-61. PubMed ID: 25894789
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Type I interferon signature in systemic lupus erythematosus.
    Bezalel S; Guri KM; Elbirt D; Asher I; Sthoeger ZM
    Isr Med Assoc J; 2014 Apr; 16(4):246-9. PubMed ID: 24834763
    [TBL] [Abstract][Full Text] [Related]  

  • 55. After half-century's wait, approval paves path for new lupus drugs.
    Ledford H
    Nat Med; 2011 Apr; 17(4):400. PubMed ID: 21475219
    [No Abstract]   [Full Text] [Related]  

  • 56. Blood Genomics Identifies Three Subtypes of Systemic Lupus Erythematosus: "IFN-High," "NE-High," and "Mixed".
    Cui M; Li T; Yan X; Wang C; Shen Q; Ren H; Li L; Zhang R
    Mediators Inflamm; 2021; 2021():6660164. PubMed ID: 34305454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP; D'Cruz DP
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pharmacological actions of anifrolumab (Saphnelo
    Ueha T; Kusuda M; Shibata S; Hirata M; Ozaki N
    Nihon Yakurigaku Zasshi; 2022; 157(4):271-279. PubMed ID: 35781459
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development.
    Cruciani C; Gatto M; Iaccarino L; Doria A; Zen M
    Expert Opin Investig Drugs; 2024 Aug; 33(8):801-814. PubMed ID: 38958085
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
    Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
    Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.